Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

2021396 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 6, pp. 779-789

Field-Weighted Citation Impact: 28.55